Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

GBI Research
February 10, 2011
100 Pages - SKU: XGBR6130342
  • Executive Summary
    • (Table) Figure 1: Key Small Molecule Drugs, Global Sales ($m), 2007-2009
    • (Table) Figure 2: Definition of Advanced Therapy Medicinal Products by European Commission
  • Targeted Therapeutics: Introduction
    • GBI Research Guidance
  • Targeted Therapeutics: Overview
    • Introduction
    • Targeted Therapy is the Need of the Hour
      • High Side Effects and Toxic Effects of Conventional Therapy
      • Variable Efficacy Rate of Conventional Drugs at the Affected Site
      • Resistance Developed to Conventional Drugs Used to Treat Infections
    • Targeted Therapeutics Market Drivers and Restraints
      • (Table) Figure 3: Targeted Therapeutics, Global, Market Drivers and Restraints, 2010
      • Targeted Therapeutics Market Drivers
      • Targeted Therapeutics Market Restraints
  • Targeted Therapeutics: Major Types of Targeted Therapeutics
    • Small Molecules
      • Overview
        • (Table) Key Small Molecule Drugs Used For Targeted Therapeutics and Their Indications, 2010
        • (Table) Figure 4: Key Small Molecule Drugs, Global Sales ($m), 2007- 2009
        • (Table) Key Small Molecule Drugs, Global, Sales Value ($m), 2007-2009
    • Innovative Small Molecule Therapeutics Market Drivers and Restraints
      • (Table) Figure 5: Small Molecule Therapeutics, Global, Market Drivers and Restraints, 2010
      • Small Molecule Therapeutics Market Drivers
      • Innovative Small Molecule Therapeutics Market Restraints
      • Profiles of Key Pipeline Molecules
    • Proteins/Peptide Drugs
      • Overview
        • (Table) Key Protein/Peptide Drugs, Generic Names and Approved Indications, 2010
        • (Table) Figure 6: Key Protein/Peptide Drugs, Global Sales ($m), 2007-2009
        • (Table) Key Protein/Peptide Drugs, Global, Sales Value ($m), 2007-2009
    • Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints
      • (Table) Figure 7: Protein/Peptide Drug Therapeutics, Global, Market Drivers and Restraints, 2010
      • Peptides/Protein Drug Therapeutics Market Drivers
      • Peptides/Protein Drug Therapeutics Market Restraints
      • Profiles of Key Pipeline Molecules
    • Monoclonal Antibodies (MAbs) and Antibody Like Structures
      • Overview
        • (Table) Key Monoclonal Antibodies (MAbs) and Their Approved Indications
        • (Table) Figure 8: Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009
        • (Table) Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009
    • Monoclonal Antibody Therapeutics, Market Drivers and Restraints
      • (Table) Figure 9: Monoclonal Antibody Therapeutics, Global, Market Drivers and Restraints, 2010
      • Monoclonal Antibody Therapeutics Market Drivers
      • Global Monoclonal Antibody Market Restraints
      • Profiles of Key Pipeline Molecules (MAb)
    • RNA Interference
      • Overview
    • RNA Interference Therapeutics Market Drivers and Restraints
      • (Table) Figure 10: RNA Interference Therapeutics, Global, Market Drivers and Restraints, 2010
      • RNA Interference Therapeutics Market Drivers
      • RNA Interference Therapeutics Market Restraints
      • Profiles of Key Pipeline Molecules (RNA)
    • Stem Cell Therapies
      • Overview
        • (Table) Figure 11: Types Of Stem Cells, Depending Upon Their Potential
    • Stem Cell Therapeutics Market Drivers and Restraints
      • (Table) Figure 12: Stem Cell Therapeutics, Global, Market Drivers and Restraints, 2010
      • Stem Cell Therapeutics Market Drivers
      • Stem Cell Therapeutics Market Restraints
      • Profile of Key Late Stage Therapies
    • Gene Therapy
      • Overview
    • Gene Therapy Market Drivers and Restraints
      • (Table) Figure 13: Gene Therapy, Global, Market Drivers and Restraints, 2010
      • Gene Therapy Market Drivers
      • Gene Therapy Market Restraints
      • Key Pipeline Candidates
  • Targeted Therapeutics: Regulatory Landscape
    • The US Regulatory Landscape Scenario
      • National Institute for Health (NIH)
      • FDA
    • EU Regulatory Landscape Scenario
      • Committee for Advanced Therapies (CAT)
        • (Table) Figure 14: Definition of Advanced Therapy Medicinal Products by the European Commission
        • (Table) List of Key EMA Directives and Guidelines for GTMPs
  • Targeted Therapeutics: Competitive Landscape
    • Antisoma
      • Overview
      • Key Deals
    • AVI BioPharma
      • Overview
      • Key Deals
    • Biogen
      • Overview
      • Key Deals
    • Cephalon
      • Overview
      • Key Deals
    • Eli Lilly
      • Overview
      • Key Deals
    • Forest Laboratories
      • Overview
      • Key Deals
    • Genmab
      • Overview
      • Key Deals
    • Gilead Sciences
      • Overview
      • Key Deals
    • Hoffmann La- Roche (Genentech)
      • Overview
      • Key Deals
    • Isis Pharmaceuticals
      • Overview
      • Key Deals
    • Johnson and Johnson (J&J)
      • Overview
      • Key Deals
    • Mesoblast Limited
      • Overview
      • Key Deals
    • Pfizer
      • Overview
      • Key Deals
    • UCB
      • Overview
      • Key Deals
  • Targeted Therapeutics Market – Appendix
    • Market Definitions
    • List of Abbreviations
    • Research Methodology
      • Coverage
      • Secondary Research
      • Primary Research
      • Expert Panel Validation
    • Contact Us
    • Disclaimer
    • Sources
 

SELECT A LICENSE

    Online Download  USD 3,500  
    Global Site License  USD 10,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!